Go Pro
→ Sell Tesla, Buy the New King of FSD Cars (From Chaikin Analytics) (Ad)tc pixel Free LFCR Stock Alerts

Lifecore Biomedical (LFCR) Financials

Lifecore Biomedical logo
$4.72 -0.03 (-0.53%)
As of 02:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Lifecore Biomedical

Annual Income Statements for Lifecore Biomedical

This table shows Lifecore Biomedical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 5/25/2025
Net Income / (Loss) Attributable to Common Shareholders		 14 -12 11 25 0.41 -38 -32 -117 -100 12 -44
Consolidated Net Income / (Loss)		 14 -11 11 25 0.41 -38 -32 -117 -100 12 -39
Net Income / (Loss) Continuing Operations		 14 -12 10 26 2.12 -22 -23 -15 -64 9.33 -39
Total Pre-Tax Income 		21 -20 14 16 3.64 -31 -30 -21 -64 9.51 -39
Total Operating Income		 18 -21 15 14 5.48 -26 -8.82 -12 -22 -8.84 -17
Total Gross Profit		 65 67 79 78 81 39 39 39 28 42 40
Total Revenue		 539 477 470 524 558 160 101 111 103 128 129
Operating Revenue		 539 477 470 524 558 160 101 111 103 128 129
Total Cost of Revenue		 474 410 391 446 477 121 62 72 75 86 89
Operating Cost of Revenue		 474 410 391 446 477 121 62 72 75 86 89
Total Operating Expenses		 47 87 65 65 76 65 48 51 50 51 58
Selling, General & Admin Expense		 40 46 52 52 62 41 28 35 39 40 44
Research & Development Expense		 6.99 7.23 9.47 13 11 7.58 6.68 7.84 8.74 8.58 8.26
Restructuring Charge		 - - - 0.00 0.00 4.05 13 8.36 4.18 1.66 -1.75
Other Special Charges / (Income)		 0.00 0.00 2.58 - 0.00 0.00 - - - 0.00 6.99
Total Other Income / (Expense), net		 3.01 0.93 -0.49 2.81 -1.84 -4.77 -21 -8.90 -42 18 -21
Interest & Investment Income		 1.73 1.72 1.67 1.86 1.80 0.07 0.05 - - -18 -22
Other Income / (Expense), net		 3.11 1.20 0.90 2.90 1.60 -0.20 -11 6.57 -0.81 36 0.41
Income Tax Expense		 7.75 -7.70 4.04 -9.36 1.52 -8.77 -6.35 -5.21 0.31 0.18 0.04
Net Income / (Loss) Discontinued Operations		 - 0.54 0.54 -0.84 -1.71 -16 -8.86 -101 -35 2.68 0.00
Preferred Stock Dividends Declared		 - - - - - - - - - 0.00 5.64
Basic Earnings per Share		 $0.50 ($0.43) $0.39 $0.90 $0.01 ($1.31) ($1.10) ($3.97) ($3.32) $0.39 ($1.27)
Weighted Average Basic Shares Outstanding		 26.88M 27.04M 27.28M 27.54M 28.36M 29.16M 29.29M 29.47M 29.96M 30.47M 34.82M
Diluted Earnings per Share		 $0.50 ($0.43) $0.38 $0.89 $0.01 ($1.31) ($1.10) ($3.97) ($3.32) $0.33 ($1.27)
Weighted Average Diluted Shares Outstanding		 27.34M 27.04M 27.65M 27.92M 28.61M 29.16M 29.29M 29.47M 29.96M 36.66M 34.82M
Weighted Average Basic & Diluted Shares Outstanding		 27.10M 27.10M 27.20M 27.60M 41.10M 29.24M 29.46M - - 30.90M 37.41M

Quarterly Income Statements for Lifecore Biomedical

This table shows Lifecore Biomedical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 5/26/2024 8/25/2024 11/24/2024 2/23/2025 5/25/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 14 16 -7.08 -16 -8.70 -16 -2.05 -16
Consolidated Net Income / (Loss)		 -11 14 16 -7.08 -16 -6.57 -15 -1.15 -15
Net Income / (Loss) Continuing Operations		 -13 14 15 -7.09 -16 -6.57 -15 -1.15 -15
Total Pre-Tax Income 		-13 14 15 -7.14 -16 -6.53 -15 -1.11 -15
Total Operating Income		 -8.61 -1.48 -0.90 2.15 -12 -1.96 -9.03 5.33 -4.67
Total Gross Profit		 2.73 9.96 12 17 5.39 11 9.85 14 4.46
Total Revenue		 25 30 36 38 25 33 35 36 23
Operating Revenue		 25 30 36 38 25 33 35 36 23
Total Cost of Revenue		 22 20 24 21 19 21 25 22 19
Operating Cost of Revenue		 22 20 24 21 19 21 25 22 19
Total Operating Expenses		 11 11 13 15 17 13 19 8.66 9.13
Selling, General & Admin Expense		 9.20 9.34 9.85 12 15 11 9.98 8.05 7.92
Research & Development Expense		 2.15 2.10 2.17 2.16 2.19 1.92 2.05 2.10 1.22
Other Special Charges / (Income)		 - - 0.00 - - - 6.85 - 0.00
Total Other Income / (Expense), net		 -3.91 16 16 -9.29 -4.67 -4.57 -5.75 -6.44 -10
Interest Expense		 3.94 4.07 - 5.79 5.38 5.47 5.59 - 7.35
Interest & Investment Income		 - - -4.29 - 0.02 - 0.11 - 0.13
Other Income / (Expense), net		 0.03 20 20 -3.50 0.70 0.90 -0.27 -0.92 -3.05
Income Tax Expense		 0.09 -0.07 0.22 -0.06 -0.03 0.04 -0.01 0.03 0.04
Preferred Stock Dividends Declared		 - 0.00 0.00 - 0.00 2.13 0.89 - 0.95
Basic Earnings per Share		 ($0.35) $0.47 $0.51 ($0.23) ($0.53) ($0.25) ($0.42) ($0.02) ($0.43)
Weighted Average Basic Shares Outstanding		 30.40M 30.46M 30.49M 30.47M 30.86M 34.36M 37.02M 34.82M 37.48M
Diluted Earnings per Share		 ($0.35) $0.39 $0.42 ($0.14) ($0.53) ($0.25) ($0.42) ($0.02) ($0.43)
Weighted Average Diluted Shares Outstanding		 30.40M 36.42M 36.61M 36.66M 30.86M 34.36M 37.02M 34.82M 37.48M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 30.90M 30.90M 37.03M 37.03M 37.41M 37.51M

Annual Cash Flow Statements for Lifecore Biomedical

This table details how cash moves in and out of Lifecore Biomedical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 5/25/2025
Net Change in Cash & Equivalents		 -0.12 -4.23 -4.39 -2.52 -1.75 -0.91 0.74 0.35 17 -11 -0.20
Net Cash From Operating Activities		 27 21 30 20 16 -17 16 -23 -17 0.26 -0.21
Net Cash From Continuing Operating Activities		 27 21 30 20 16 -17 16 -23 -17 0.26 -0.21
Net Income / (Loss) Continuing Operations		 14 -11 11 25 0.41 -38 -32 -117 -100 12 -39
Consolidated Net Income / (Loss)		 14 -11 11 25 0.41 -38 -32 -117 -100 12 -39
Depreciation Expense		 7.09 9.40 11 12 15 19 20 18 13 7.95 8.03
Non-Cash Adjustments To Reconcile Net Income		 -1.62 36 4.88 1.66 4.57 36 27 86 49 24 33
Changes in Operating Assets and Liabilities, net		 7.40 -13 3.60 -19 -4.19 -33 1.89 -9.93 20 -44 -2.19
Net Cash From Investing Activities		 -34 -40 -25 -36 -97 -24 -12 80 -4.81 -18 -6.42
Net Cash From Continuing Investing Activities		 -34 -40 -25 -36 -97 -24 -12 80 -4.81 -18 -6.42
Purchase of Property, Plant & Equipment		 -18 -40 -23 -34 -45 -27 -25 -30 -21 -18 -13
Sale of Property, Plant & Equipment		 1.07 0.13 0.08 0.10 0.26 2.43 13 1.14 0.00 0.00 7.00
Net Cash From Financing Activities		 7.71 15 -8.80 13 79 40 -3.42 -57 40 7.51 6.42
Net Cash From Continuing Financing Activities		 7.71 15 -8.80 13 79 40 -3.42 -57 40 7.51 6.42
Repayment of Debt		 -37 -37 -63 -14 -40 -107 -273 -131 -184 -148 -147
Issuance of Debt		 45 53 55 33 119 147 270 75 181 150 129
Issuance of Common Equity		 0.12 0.32 0.71 0.06 0.33 0.03 0.00 0.00 4.82 0.00 24
Other Financing Activities, net		 -0.34 -0.25 -0.48 -5.57 -0.70 -0.21 -0.41 -0.79 -0.27 5.57 1.13

Quarterly Cash Flow Statements for Lifecore Biomedical

This table details how cash moves in and out of Lifecore Biomedical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 5/26/2024 8/25/2024 11/24/2024 2/23/2025 5/25/2025 3/31/2026
Net Change in Cash & Equivalents		 -10 -5.42 -0.15 5.39 -2.94 3.94 -4.04 2.85 3.33
Net Cash From Operating Activities		 -8.33 1.29 -1.42 8.64 -0.61 -6.11 1.20 5.35 4.70
Net Cash From Continuing Operating Activities		 -8.33 1.29 -1.42 8.64 -0.61 -6.11 1.20 5.35 4.70
Net Income / (Loss) Continuing Operations		 -11 14 16 -7.08 -16 -6.57 -15 -1.15 -15
Consolidated Net Income / (Loss)		 -11 14 16 -7.08 -16 -6.57 -15 -1.15 -15
Depreciation Expense		 2.17 1.77 2.01 2.25 1.99 2.04 2.08 1.91 2.31
Non-Cash Adjustments To Reconcile Net Income		 4.58 5.25 6.93 6.58 6.97 8.20 14 3.69 12
Changes in Operating Assets and Liabilities, net		 -4.33 -20 -26 6.89 6.65 -9.79 0.23 0.89 5.48
Net Cash From Investing Activities		 -5.05 -4.26 -6.37 -2.64 -3.42 -2.47 1.54 -2.10 -1.12
Net Cash From Continuing Investing Activities		 -5.05 -4.26 -6.37 -2.64 -3.42 -2.47 1.54 -2.10 -1.12
Purchase of Property, Plant & Equipment		 -5.05 -4.26 -6.37 -2.64 -3.42 -2.47 -5.46 -2.10 -1.12
Sale of Property, Plant & Equipment		 - - - - - - - - 0.00
Net Cash From Financing Activities		 2.93 -2.45 7.64 -0.61 1.09 13 -6.78 -0.40 -0.26
Net Cash From Continuing Financing Activities		 2.93 -2.45 7.64 -0.61 1.09 13 -6.78 -0.40 -0.26
Repayment of Debt		 0.00 -0.12 2.62 -150 -30 -11 -6.75 -129 -37
Issuance of Debt		 2.28 - - 150 32 - - - 36
Other Financing Activities, net		 0.65 -0.04 5.02 -0.09 -0.59 1.97 -0.05 -0.16 0.00

Annual Balance Sheets for Lifecore Biomedical

This table presents Lifecore Biomedical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 12/31/2025
Total Assets		 346 343 359 405 519 541 502 275 254 254 232
Total Current Assets		 93 86 81 97 133 157 145 117 94 81 82
Cash & Equivalents		 14 9.89 6.00 2.90 1.08 0.36 0.76 0.99 19 8.46 17
Accounts Receivable		 46 46 46 54 70 76 32 38 29 27 26
Inventories, net		 25 26 24 32 54 66 34 36 41 40 29
Prepaid Expenses		 5.46 4.47 3.50 7.96 8.26 14 1.50 2.05 4.92 1.44 1.92
Other Current Assets		 - - - - - - - - - 4.07 7.66
Plant, Property, & Equipment, net		 84 121 133 160 200 192 107 119 134 149 127
Total Noncurrent Assets		 169 135 144 148 186 192 204 39 25 24 23
Goodwill		 50 50 55 55 77 69 14 14 14 14 14
Other Noncurrent Operating Assets		 63 64 67 72 64 84 17 8.44 7.20 5.68 8.70
Total Liabilities & Shareholders' Equity		 346 343 359 405 519 541 502 275 254 254 232
Total Liabilities		 126 130 130 152 249 310 300 187 218 200 198
Total Current Liabilities		 56 56 51 88 137 164 102 177 39 39 24
Accounts Payable		 35 31 25 35 54 52 12 13 22 16 6.21
Accrued Expenses		 5.21 7.77 9.05 8.71 10 9.98 3.01 6.48 7.14 23 17
Total Noncurrent Liabilities		 70 74 79 64 112 146 198 10 179 161 175
Long-Term Debt		 34 46 42 37 87 101 165 0.00 101 124 141
Other Noncurrent Operating Liabilities		 1.69 1.74 8.39 5.28 5.27 31 20 7.85 75 37 33
Commitments & Contingencies		 - - - - - - - - 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - 0.00 0.00 39 43 48
Total Equity & Noncontrolling Interests		 220 212 228 253 270 231 202 88 -4.23 11 -14
Total Preferred & Common Equity		 218 211 227 253 270 231 202 88 -4.23 11 -14
Total Common Equity		 218 211 227 253 270 231 202 88 -4.23 11 -14
Common Stock		 133 137 142 142 160 163 166 167 174 178 209
Retained Earnings		 85 73 84 109 110 71 38 -79 -179 -167 -223

Quarterly Balance Sheets for Lifecore Biomedical

This table presents Lifecore Biomedical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 8/25/2024 11/24/2024 2/23/2025 3/31/2026
Total Assets		 246 246 246 247 255 238 225
Total Current Assets		 83 77 76 74 82 84 78
Cash & Equivalents		 8.64 3.22 3.07 5.52 9.46 5.42 21
Accounts Receivable		 27 30 31 25 30 28 19
Inventories, net		 42 41 40 42 39 35 28
Prepaid Expenses		 5.87 1.85 1.97 1.88 2.89 2.55 1.80
Other Current Assets		 - - - - - 6.15 7.45
Plant, Property, & Equipment, net		 136 143 145 149 151 128 126
Total Noncurrent Assets		 27 26 25 24 23 25 22
Goodwill		 14 14 14 14 14 14 14
Other Noncurrent Operating Assets		 8.47 8.11 6.64 5.80 4.87 7.18 8.47
Total Liabilities & Shareholders' Equity		 246 246 246 247 255 238 225
Total Liabilities		 219 203 187 207 196 190 205
Total Current Liabilities		 35 40 37 41 35 31 20
Accounts Payable		 16 19 16 18 15 7.41 7.01
Accrued Expenses		 4.86 7.66 8.89 11 9.87 20 13
Total Noncurrent Liabilities		 184 163 150 167 160 159 184
Long-Term Debt		 107 109 116 127 119 124 148
Other Noncurrent Operating Liabilities		 74 54 33 34 36 35 36
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 40 41 42 43 44 45 49
Total Equity & Noncontrolling Interests		 -14 1.42 18 -3.94 15 2.23 -28
Total Preferred & Common Equity		 -14 1.42 18 -3.94 15 2.23 -28
Total Common Equity		 -14 1.42 18 -3.94 15 2.23 -28
Common Stock		 176 176 177 179 207 206 210
Retained Earnings		 -189 -175 -159 -183 -191 -204 -238

Annual Metrics And Ratios for Lifecore Biomedical

This table displays calculated financial ratios and metrics derived from Lifecore Biomedical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 5/25/2025
DEI Shares Outstanding		 26,947,394.00 27,073,243.00 27,305,179.00 27,564,428.00 29,182,631.00 29,182,178.00 29,332,832.00 29,482,538.00 30,322,169.00 - 37,025,331.00
DEI Adjusted Shares Outstanding		 26,947,394.00 27,073,243.00 27,305,179.00 27,564,428.00 29,182,631.00 29,182,178.00 29,332,832.00 29,482,538.00 30,322,169.00 - 37,025,331.00
DEI Earnings Per Adjusted Shares Outstanding		 0.50 -0.43 0.39 0.90 0.01 -1.31 -1.10 -3.96 -3.28 - -1.20
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 13.10% -11.56% -1.50% 11.59% 6.36% -71.29% -36.98% 10.31% -7.19% 24.20% 0.47%
EBITDA Growth		 -23.18% -135.01% 361.59% 10.11% -22.82% -132.43% 101.04% 17,025.33% -173.41% 486.71% -124.78%
EBIT Growth		 -28.56% -190.08% 180.13% 5.90% -57.09% -468.49% 24.08% 73.64% -333.31% 222.11% -161.00%
NOPAT Growth		 -9.57% -222.36% 172.63% 103.53% -85.05% -667.50% 65.90% -33.64% -84.85% 43.15% -39.17%
Net Income Growth		 -29.04% -183.41% 193.27% 133.43% -98.35% -9,392.21% 15.44% -261.41% 14.70% 112.07% -422.29%
EPS Growth		 -29.58% -186.00% 188.37% 134.21% -98.88% -13,200.00% 16.03% -260.91% 16.37% 109.64% -484.85%
Operating Cash Flow Growth		 26.48% -22.00% 43.71% -33.71% -19.01% -206.37% 196.66% -237.17% 22.80% 98.76% -180.16%
Free Cash Flow Firm Growth		 -428.61% -134.42% 94.50% -1,469.50% -262.54% 77.27% 1,315.41% -111.21% 264.39% -222.81% 84.93%
Invested Capital Growth		 10.89% 6.08% 4.59% 16.98% 29.63% 0.69% -62.10% 12.75% -34.62% 41.72% -1.77%
Revenue Q/Q Growth		 -4.95% -4.36% -1.30% 16.99% 2.14% -72.73% 172.13% 226.62% 69.54% 5.55% -1.11%
EBITDA Q/Q Growth		 -85.15% 94.45% -15.20% 34.75% -18.02% -65.82% 101.83% -41.43% -69.25% 16.78% 35.05%
EBIT Q/Q Growth		 -88.41% 89.73% -22.98% 73.18% -47.07% -13.92% 17.31% -318.93% -15.04% 26.40% 25.49%
NOPAT Q/Q Growth		 -93.66% 89.10% -18.78% 36.11% -61.26% -12.76% 26.12% -162.08% -10.20% 29.72% 15.57%
Net Income Q/Q Growth		 -92.49% 93.66% -17.97% 17.15% -93.94% -63.88% 28.15% -83.81% 14.16% 159.51% 13.29%
EPS Q/Q Growth		 0.00% 0.00% -19.15% 18.67% -96.00% -63.75% 29.03% -84.65% 14.87% 137.21% 8.63%
Operating Cash Flow Q/Q Growth		 29.30% 5.54% -20.46% -26.63% -5.36% -195.49% 883.21% -39.69% -10.90% 98.05% -107.66%
Free Cash Flow Firm Q/Q Growth		 -107.97% 79.21% -119.02% -13.82% 12.35% -2.18% 1,008.02% -119.07% 28.25% -5,536.27% -31.48%
Invested Capital Q/Q Growth		 -0.44% 1.68% 4.58% 6.91% 0.67% 0.28% -58.92% -23.52% -36.32% -3.86% 0.09%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 12.13% 14.00% 16.86% 14.94% 14.53% 24.61% 38.60% 35.11% 27.10% 32.63% 31.27%
EBITDA Margin		 5.31% -2.10% 5.59% 5.51% 4.00% -4.52% 0.07% 11.54% -9.13% 28.43% -6.84%
Operating Margin		 3.42% -4.33% 3.12% 2.59% 0.98% -16.17% -8.75% -10.60% -21.11% -6.90% -13.38%
EBIT Margin		 4.00% -4.07% 3.31% 3.15% 1.27% -16.29% -19.62% -4.69% -21.89% 21.52% -13.07%
Profit (Net Income) Margin		 2.55% -2.40% 2.27% 4.75% 0.07% -23.86% -32.01% -104.89% -96.41% 9.37% -30.04%
Tax Burden Percent		 63.92% 58.13% 75.32% 151.99% 11.29% 124.62% 108.42% 564.19% 155.74% 126.27% 100.11%
Interest Burden Percent		 99.55% 101.37% 91.05% 99.46% 51.45% 117.54% 150.50% 396.53% 282.79% 34.47% 229.67%
Effective Tax Rate		 36.08% 0.00% 28.50% -57.10% 41.70% 0.00% 0.00% 0.00% 0.00% 1.92% 0.00%
Return on Invested Capital (ROIC)		 4.99% -5.64% 3.89% 7.14% 0.86% -4.32% -2.13% -4.86% -10.25% -6.10% -7.20%
ROIC Less NNEP Spread (ROIC-NNEP)		 13.06% 1.87% 4.27% 13.22% -1.69% -16.20% -37.52% -441.05% -106.79% 15.08% -29.97%
Return on Net Nonoperating Assets (RNNOA)		 1.47% 0.34% 0.96% 3.23% -0.70% -10.92% -12.79% -75.70% -151.75% 33.10% -69.21%
Return on Equity (ROE)		 6.46% -5.29% 4.85% 10.37% 0.16% -15.24% -14.92% -80.56% -162.01% 27.00% -76.41%
Cash Return on Invested Capital (CROIC)		 -5.33% -11.54% -0.60% -8.52% -24.95% -5.01% 87.93% -16.85% 31.61% -40.62% -5.41%
Operating Return on Assets (OROA)		 6.53% -5.64% 4.44% 4.32% 1.53% -4.92% -3.79% -1.34% -8.56% 10.88% -6.83%
Return on Assets (ROA)		 4.16% -3.32% 3.05% 6.53% 0.09% -7.20% -6.19% -30.06% -37.70% 4.73% -15.70%
Return on Common Equity (ROCE)		 6.41% -5.25% 4.81% 10.34% 0.16% -15.24% -14.92% -80.56% -110.18% 2.15% -9.54%
Return on Equity Simple (ROE_SIMPLE)		 6.28% -5.43% 4.71% 9.87% 0.15% -16.53% -15.99% -132.90% 2,353.74% 106.17% 0.00%
Net Operating Profit after Tax (NOPAT)		 12 -14 10 21 3.19 -18 -6.18 -8.25 -15 -8.67 -12
NOPAT Margin		 2.19% -3.03% 2.23% 4.07% 0.57% -11.32% -6.12% -7.42% -14.77% -6.76% -9.37%
Net Nonoperating Expense Percent (NNEP)		 -8.06% -7.51% -0.38% -6.09% 2.55% 11.88% 35.39% 436.18% 96.54% -21.18% 22.77%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - - -9.41%
Cost of Revenue to Revenue		 87.87% 86.00% 83.14% 85.06% 85.47% 75.39% 61.40% 64.89% 72.90% 67.37% 68.73%
SG&A Expenses to Revenue		 7.41% 9.68% 11.17% 9.91% 11.13% 25.41% 27.48% 31.15% 37.74% 31.55% 34.18%
R&D to Revenue		 1.30% 1.52% 2.02% 2.44% 2.06% 4.74% 6.63% 7.05% 8.46% 6.69% 6.41%
Operating Expenses to Revenue		 8.71% 18.33% 13.74% 12.35% 13.55% 40.77% 47.35% 45.71% 48.21% 39.52% 44.65%
Earnings before Interest and Taxes (EBIT)		 22 -19 16 16 7.08 -26 -20 -5.22 -23 28 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 29 -10 26 29 22 -7.23 0.08 13 -9.43 36 -8.81
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.76 1.47 1.64 1.53 1.02 1.35 1.74 3.31 0.00 15.17 186.24
Price to Tangible Book Value (P/TBV)		 3.42 2.22 2.50 2.20 1.86 2.52 1.91 4.17 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.71 0.65 0.79 0.74 0.49 1.95 3.48 2.62 2.33 1.34 1.93
Price to Earnings (P/E)		 28.43 0.00 35.20 15.60 668.86 0.00 0.00 0.00 0.00 14.29 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.52% 0.00% 2.84% 6.41% 0.15% 0.00% 0.00% 0.00% 0.00% 7.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.67 1.38 1.53 1.42 1.01 1.19 3.41 2.38 3.08 1.96 2.49
Enterprise Value to Revenue (EV/Rev)		 0.77 0.76 0.90 0.87 0.76 3.13 5.40 3.85 3.51 2.55 3.21
Enterprise Value to EBITDA (EV/EBITDA)		 14.49 0.00 16.09 15.82 18.96 0.00 7,256.71 33.34 0.00 8.97 0.00
Enterprise Value to EBIT (EV/EBIT)		 19.25 0.00 27.12 27.74 59.76 0.00 0.00 0.00 0.00 11.85 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 35.18 0.00 40.26 21.43 132.47 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 15.60 17.49 14.15 23.12 26.39 0.00 33.04 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 2.13 0.00 7.71 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.19 0.29 0.24 0.29 0.55 0.82 0.96 1.57 2.90 2.25 2.68
Long-Term Debt to Equity		 0.16 0.23 0.20 0.16 0.32 0.44 0.82 0.00 2.88 2.24 2.68
Financial Leverage		 0.11 0.18 0.22 0.24 0.42 0.67 0.34 0.17 1.42 2.20 2.31
Leverage Ratio		 1.55 1.59 1.59 1.59 1.77 2.12 2.41 2.68 4.30 5.70 4.87
Compound Leverage Factor		 1.55 1.62 1.45 1.58 0.91 2.49 3.63 10.63 12.15 1.97 11.18
Debt to Total Capital		 16.19% 22.36% 19.13% 22.41% 35.55% 45.17% 48.98% 61.14% 74.34% 69.23% 72.81%
Short-Term Debt to Total Capital		 3.18% 4.16% 2.81% 9.81% 14.74% 21.11% 7.33% 61.14% 0.42% 0.44% 0.00%
Long-Term Debt to Total Capital		 13.01% 18.20% 16.32% 12.60% 20.80% 24.06% 41.66% 0.00% 73.91% 68.79% 72.81%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.64% 0.59% 0.55% 0.00% 0.00% 0.00% 0.00% 0.00% 28.76% 24.31% 26.43%
Common Equity to Total Capital		 83.17% 77.05% 80.32% 77.59% 64.45% 54.83% 51.02% 38.86% -3.09% 6.46% 0.77%
Debt to EBITDA		 1.48 -6.09 2.06 2.52 6.68 -26.31 2,585.36 10.76 -10.78 3.33 -14.41
Net Debt to EBITDA		 0.99 -5.11 1.83 2.42 6.63 -26.26 2,575.19 10.68 -8.76 3.09 -13.47
Long-Term Debt to EBITDA		 1.19 -4.96 1.75 1.42 3.91 -14.01 2,198.69 0.00 -10.72 3.31 -14.41
Debt to NOPAT		 3.60 -4.23 5.15 3.42 46.68 -10.51 -31.40 -16.74 -6.66 -13.98 -10.52
Net Debt to NOPAT		 2.41 -3.55 4.57 3.28 46.34 -10.49 -31.27 -16.62 -5.41 -13.01 -9.84
Long-Term Debt to NOPAT		 2.90 -3.45 4.39 1.92 27.32 -5.60 -26.70 0.00 -6.62 -13.89 -10.52
Altman Z-Score		 4.06 3.04 3.60 3.36 2.07 0.91 0.98 0.61 0.05 0.66 0.16
Noncontrolling Interest Sharing Ratio		 0.79% 0.76% 0.72% 0.32% 0.00% 0.00% 0.00% 0.00% 31.99% 92.04% 87.52%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.66 1.53 1.58 1.10 0.97 0.96 1.43 0.66 2.39 2.08 2.84
Quick Ratio		 1.08 1.00 1.01 0.64 0.52 0.47 0.32 0.22 1.22 1.02 1.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 -30 -1.62 -25 -92 -21 255 -29 47 -58 -9.07
Operating Cash Flow to CapEx		 161.91% 52.47% 130.17% 59.06% 36.02% -70.27% 133.80% -78.45% -81.19% -1.21% -3.21%
Free Cash Flow to Firm to Interest Expense		 -6.89 -14.87 -0.53 -13.07 -17.66 -4.52 25.42 -1.85 1.14 -3.19 0.00
Operating Cash Flow to Interest Expense		 14.55 10.45 9.75 10.14 3.06 -3.67 1.64 -1.46 -0.42 -0.01 0.00
Operating Cash Flow Less CapEx to Interest Expense		 5.56 -9.46 2.26 -7.03 -5.44 -8.89 0.41 -3.32 -0.94 -1.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.63 1.38 1.34 1.37 1.21 0.30 0.19 0.29 0.39 0.51 0.52
Accounts Receivable Turnover		 11.83 10.27 10.18 10.51 9.03 2.20 1.87 3.18 3.07 4.26 4.62
Inventory Turnover		 19.04 16.22 15.89 16.09 11.09 2.00 1.24 2.07 1.96 2.14 2.45
Fixed Asset Turnover		 6.80 4.65 3.70 3.58 3.10 0.82 0.67 0.99 0.82 0.91 0.93
Accounts Payable Turnover		 14.12 12.44 14.09 15.07 10.75 2.29 1.96 5.88 4.30 4.50 7.21
Days Sales Outstanding (DSO)		 30.87 35.54 35.86 34.74 40.41 166.20 195.03 114.66 119.00 85.62 78.98
Days Inventory Outstanding (DIO)		 19.17 22.50 22.97 22.69 32.92 182.14 295.36 176.75 186.27 170.69 148.92
Days Payable Outstanding (DPO)		 25.85 29.33 25.90 24.23 33.95 159.73 186.42 62.11 84.96 81.17 50.59
Cash Conversion Cycle (CCC)		 24.18 28.71 32.93 33.20 39.37 188.62 303.96 229.30 220.31 175.15 177.30
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 249 264 276 323 418 421 160 180 118 167 166
Invested Capital Turnover		 2.28 1.86 1.74 1.75 1.51 0.38 0.35 0.66 0.69 0.90 0.77
Increase / (Decrease) in Invested Capital		 24 15 12 47 96 2.89 -261 20 -62 49 -3.00
Enterprise Value (EV)		 415 363 422 457 423 501 544 428 363 327 414
Market Capitalization		 385 310 373 387 275 311 351 291 241 172 249
Book Value per Share		 $8.11 $7.78 $8.30 $9.16 $9.26 $7.92 $6.88 $2.98 ($0.14) $0.37 $0.04
Tangible Book Value per Share		 $4.18 $5.16 $5.47 $6.39 $5.08 $4.23 $6.27 $2.37 ($0.74) ($0.22) ($0.45)
Total Capital		 263 273 282 326 419 421 396 226 137 175 174
Total Debt		 43 61 54 73 149 190 194 138 102 121 127
Total Long-Term Debt		 34 50 46 41 87 101 165 0.00 101 121 127
Net Debt		 28 51 48 70 148 190 193 137 83 113 119
Capital Expenditures (CapEx)		 16 40 23 33 44 24 12 29 21 18 6.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 31 31 32 38 57 81 72 77 36 34 47
Debt-free Net Working Capital (DFNWC)		 45 41 38 41 58 82 72 78 55 43 55
Net Working Capital (NWC)		 37 30 30 8.69 -4.05 -7.28 43 -60 55 42 55
Net Nonoperating Expense (NNE)		 -1.92 -2.99 -0.19 -3.58 2.78 20 26 108 84 -21 27
Net Nonoperating Obligations (NNO)		 28 51 48 70 148 190 -42 92 83 113 119
Total Depreciation and Amortization (D&A)		 7.09 9.40 11 12 15 19 20 18 13 8.86 8.03
Debt-free, Cash-free Net Working Capital to Revenue		 5.80% 6.59% 6.76% 7.20% 10.16% 50.80% 71.06% 69.45% 34.93% 26.88% 36.65%
Debt-free Net Working Capital to Revenue		 8.42% 8.67% 8.04% 7.75% 10.36% 51.02% 71.82% 70.34% 53.42% 33.47% 43.07%
Net Working Capital to Revenue		 6.87% 6.28% 6.35% 1.66% -0.73% -4.55% 43.07% -53.84% 52.86% 32.87% 43.07%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.50 ($0.43) $0.39 $0.90 $0.01 ($1.31) ($1.12) $0.00 ($3.32) $0.40 ($1.27)
Adjusted Weighted Average Basic Shares Outstanding		 26.88K 27.04M 27.28M 27.54M 28.36M 29.16M 29.29M 0.00 29.96M 30.47M 34.82M
Adjusted Diluted Earnings per Share		 $0.50 ($0.43) $0.38 $0.89 $0.01 ($1.31) ($1.12) $0.00 ($3.32) $0.32 ($1.27)
Adjusted Weighted Average Diluted Shares Outstanding		 27.34K 27.04M 27.65M 27.92M 28.61M 29.16M 29.29M 0.00 29.96M 36.66M 34.82M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.01M 27.23M 27.51M 27.74M 29.15M 29.24M 29.46M 0.00 0.00 30.90M 37.41M
Normalized Net Operating Profit after Tax (NOPAT)		 12 9.36 12 9.51 4.36 -6.21 3.17 -2.40 -12 -7.05 -8.40
Normalized NOPAT Margin		 2.19% 1.96% 2.63% 1.81% 0.78% -3.88% 3.14% -2.16% -11.94% -5.50% -6.52%
Pre Tax Income Margin		 3.98% -4.13% 3.02% 3.13% 0.65% -19.15% -29.53% -18.59% -61.90% 7.42% -30.01%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 11.79 -9.78 5.09 8.45 1.35 -5.61 -1.97 -0.34 -0.55 1.53 0.00
NOPAT to Interest Expense		 6.45 -7.27 3.43 10.95 0.61 -3.90 -0.62 -0.53 -0.37 -0.48 0.00
EBIT Less CapEx to Interest Expense		 2.80 -29.69 -2.40 -8.72 -7.15 -10.83 -3.20 -2.20 -1.07 0.54 0.00
NOPAT Less CapEx to Interest Expense		 -2.54 -27.18 -4.06 -6.23 -7.89 -9.12 -1.84 -2.40 -0.89 -1.47 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 1.43% -2.17% 1.55% 0.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 1.43% -2.17% 1.55% 0.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lifecore Biomedical

This table displays calculated financial ratios and metrics derived from Lifecore Biomedical's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 5/26/2024 8/25/2024 11/24/2024 2/23/2025 5/25/2025 3/31/2026
DEI Shares Outstanding		 30,322,169.00 30,322,169.00 30,322,169.00 - - - - 37,025,331.00 37,466,352.00
DEI Adjusted Shares Outstanding		 30,322,169.00 30,322,169.00 30,322,169.00 - - - - 37,025,331.00 37,466,352.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.35 0.47 0.52 - - - - -0.06 -0.43
Growth Metrics		 - - - - - - - - -
Revenue Growth		 3.36% 37.90% 34.55% 21.64% 0.75% 8.01% -1.54% -3.80% -6.12%
EBITDA Growth		 -827.44% 855.61% 762.63% 120.21% -38.62% -95.10% -133.90% 856.28% 39.21%
EBIT Growth		 -147.24% 426.53% 400.16% 80.99% -26.83% -105.82% -148.19% 425.72% 29.12%
NOPAT Growth		 -163.10% 60.23% 80.71% 132.35% -34.48% 7.95% -616.54% 148.00% 59.67%
Net Income Growth		 1.93% 211.03% 142.82% 81.97% -50.92% -146.22% -194.48% 83.81% 7.70%
EPS Growth		 5.41% 190.70% 135.00% 89.39% -51.43% -164.10% -211.90% 84.62% 18.87%
Operating Cash Flow Growth		 -656.49% 154.74% 87.91% 481.96% 92.28% -574.38% 184.63% -38.65% 866.72%
Free Cash Flow Firm Growth		 -160.96% -38.04% -77.29% -182.55% 66.55% -135.42% -89.69% 113.45% 124.64%
Invested Capital Growth		 0.00% -30.55% -6.13% 41.72% 28.61% 14.31% -4.26% -1.77% -8.74%
Revenue Q/Q Growth		 -21.27% 22.95% 18.42% 6.11% -34.79% 31.81% 7.95% 3.67% -36.36%
EBITDA Q/Q Growth		 -44.24% 411.97% 6.40% -95.82% -1,089.32% 111.03% -835.98% 187.55% -185.54%
EBIT Q/Q Growth		 -20.60% 312.60% 5.70% -107.01% -704.66% 90.24% -774.51% 147.41% -275.11%
NOPAT Q/Q Growth		 -29.75% 75.29% 40.79% 270.47% -639.29% 83.09% -360.90% 159.00% -187.70%
Net Income Q/Q Growth		 72.63% 232.21% 9.95% -145.31% -129.14% 59.51% -124.76% 92.23% -1,206.02%
EPS Q/Q Growth		 73.48% 211.43% 7.69% -133.33% -278.57% 52.83% -88.00% 95.74% -2,050.00%
Operating Cash Flow Q/Q Growth		 -268.21% 115.46% -210.09% 663.23% -107.44% -850.23% 119.64% 345.58% -12.10%
Free Cash Flow Firm Q/Q Growth		 -328.88% 148.50% -83.69% -555.94% 7.25% 48.64% 104.75% 525.35% 61.64%
Invested Capital Q/Q Growth		 7.01% 18.21% 16.53% -3.86% -2.89% 5.06% -2.40% 0.09% -11.08%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 11.12% 33.02% 33.31% 45.59% 21.81% 34.04% 28.01% 38.37% 19.24%
EBITDA Margin		 -26.16% 66.39% 59.65% 2.37% -36.00% 3.01% -20.54% 17.34% -23.31%
Operating Margin		 -35.13% -4.92% -2.51% 5.67% -46.89% -6.02% -25.68% 14.62% -20.14%
EBIT Margin		 -35.01% 60.53% 54.03% -3.57% -44.07% -3.26% -26.44% 12.09% -33.27%
Profit (Net Income) Margin		 -43.85% 47.16% 43.78% -18.70% -65.70% -20.18% -42.01% -3.15% -64.59%
Tax Burden Percent		 85.88% 100.29% 104.20% 99.16% 99.85% 100.66% 99.95% 102.96% 100.29%
Interest Burden Percent		 145.88% 77.68% 77.77% 527.94% 149.31% 614.11% 158.96% -25.28% 193.56%
Effective Tax Rate		 0.00% -0.46% 1.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -40.65% -3.06% -1.68% 3.58% -29.30% -3.46% -13.80% 7.86% -11.60%
ROIC Less NNEP Spread (ROIC-NNEP)		 -50.17% 9.68% 12.94% -5.21% -36.62% -8.25% -21.07% 3.70% -20.99%
Return on Net Nonoperating Assets (RNNOA)		 -187.66% 20.49% 22.13% -11.44% -122.93% -17.52% -45.86% 8.54% -86.83%
Return on Equity (ROE)		 -228.32% 17.43% 20.45% -7.86% -152.23% -20.98% -59.66% 16.40% -98.43%
Cash Return on Invested Capital (CROIC)		 -230.18% 27.09% -0.57% -40.62% -33.14% -18.75% -4.07% -5.41% 4.46%
Operating Return on Assets (OROA)		 -14.83% 25.91% 27.22% -1.81% -22.99% -1.70% -14.24% 6.32% -17.94%
Return on Assets (ROA)		 -18.58% 20.19% 22.06% -9.45% -34.27% -10.54% -22.63% -1.64% -34.83%
Return on Common Equity (ROCE)		 116.59% 11.31% 8.03% -0.63% 40.32% -3.47% -11.12% 2.05% 52.87%
Return on Equity Simple (ROE_SIMPLE)		 732.68% 0.00% -114.15% 0.00% -166.00% -92.25% -2,003.28% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.03 -1.49 -0.88 1.50 -8.11 -1.37 -6.32 3.73 -3.27
NOPAT Margin		 -24.59% -4.94% -2.47% 3.97% -32.82% -4.21% -17.98% 10.23% -14.10%
Net Nonoperating Expense Percent (NNEP)		 9.51% -12.74% -14.61% 8.79% 7.33% 4.80% 7.27% 4.17% 9.39%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.34% -0.65% - - -1.01% -5.01% 2.91% -2.74%
Cost of Revenue to Revenue		 88.88% 66.98% 66.69% 54.41% 78.19% 65.96% 71.99% 61.63% 80.76%
SG&A Expenses to Revenue		 37.50% 30.99% 27.58% 32.27% 59.85% 34.15% 28.71% 22.09% 34.14%
R&D to Revenue		 8.75% 6.96% 6.08% 5.70% 8.85% 5.91% 5.82% 5.77% 5.25%
Operating Expenses to Revenue		 46.25% 37.94% 35.82% 39.92% 68.69% 40.05% 53.69% 23.75% 39.38%
Earnings before Interest and Taxes (EBIT)		 -8.58 18 19 -1.35 -11 -1.06 -9.30 4.41 -7.72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.42 20 21 0.90 -8.89 0.98 -7.22 6.32 -5.41
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 160.25 13.84 15.17 0.00 14.62 93.19 186.24 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.44 2.03 2.01 1.34 1.44 1.73 1.59 1.93 1.09
Price to Earnings (P/E)		 0.00 0.00 0.00 14.29 28.33 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 7.00% 3.53% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.13 2.52 2.31 1.96 2.17 2.24 2.24 2.49 2.14
Enterprise Value to Revenue (EV/Rev)		 3.78 3.34 3.29 2.55 2.73 2.91 2.85 3.21 2.48
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 63.18 13.15 8.97 10.33 25.45 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 18.33 11.85 13.88 63.55 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 47.00 5,359.48 138.16 0.00 61.79
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 7.63 0.00 0.00 0.00 0.00 0.00 0.00 45.66
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 4.06 2.59 1.97 2.25 3.24 2.00 2.61 2.68 7.11
Long-Term Debt to Equity		 4.04 2.57 1.96 2.24 3.22 1.99 2.61 2.68 7.11
Financial Leverage		 3.74 2.12 1.71 2.20 3.36 2.12 2.18 2.31 4.14
Leverage Ratio		 9.25 4.51 3.65 5.70 7.45 4.91 4.53 4.87 7.84
Compound Leverage Factor		 13.49 3.50 2.84 30.11 11.13 30.14 7.20 -1.23 15.17
Debt to Total Capital		 80.25% 72.16% 66.32% 69.23% 76.41% 66.72% 72.34% 72.81% 87.67%
Short-Term Debt to Total Capital		 0.57% 0.51% 0.44% 0.44% 0.46% 0.43% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 79.68% 71.65% 65.88% 68.79% 75.94% 66.29% 72.34% 72.81% 87.67%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 29.83% 26.91% 23.66% 24.31% 25.95% 24.68% 26.36% 26.43% 29.20%
Common Equity to Total Capital		 -10.08% 0.93% 10.02% 6.46% -2.35% 8.60% 1.30% 0.77% -16.87%
Debt to EBITDA		 -6.45 18.48 3.84 3.33 3.76 8.01 -9.14 -14.41 -27.75
Net Debt to EBITDA		 -5.94 17.94 3.74 3.09 3.60 7.38 -8.74 -13.47 -23.85
Long-Term Debt to EBITDA		 -6.41 18.35 3.82 3.31 3.74 7.96 -9.14 -14.41 -27.75
Debt to NOPAT		 -5.68 -6.74 -9.48 -13.98 -10.96 -13.93 -8.67 -10.52 -20.43
Net Debt to NOPAT		 -5.23 -6.54 -9.23 -13.01 -10.49 -12.83 -8.30 -9.84 -17.56
Long-Term Debt to NOPAT		 -5.64 -6.69 -9.42 -13.89 -10.89 -13.84 -8.67 -10.52 -20.43
Altman Z-Score		 0.16 0.55 0.82 0.28 0.04 0.36 0.14 0.45 -0.31
Noncontrolling Interest Sharing Ratio		 151.07% 35.12% 60.73% 92.04% 126.49% 83.48% 81.36% 87.52% 153.71%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 2.34 1.91 2.07 2.08 1.83 2.32 2.71 2.84 3.79
Quick Ratio		 1.00 0.83 0.94 1.02 0.76 1.13 1.32 1.49 1.96
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -132 64 10 -48 -44 -23 1.08 6.73 11
Operating Cash Flow to CapEx		 -164.80% 30.23% -22.27% 327.65% -18.96% -247.37% 21.99% 254.98% 420.39%
Free Cash Flow to Firm to Interest Expense		 -33.50 15.71 0.00 -8.22 -8.22 -4.15 0.00 0.00 1.48
Operating Cash Flow to Interest Expense		 -2.12 0.32 0.00 1.49 -0.12 -1.12 0.00 0.00 0.64
Operating Cash Flow Less CapEx to Interest Expense		 -3.40 -0.73 0.00 1.04 -0.75 -1.57 0.00 0.00 0.49
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.42 0.43 0.50 0.51 0.52 0.52 0.54 0.52 0.54
Accounts Receivable Turnover		 3.91 3.41 3.81 4.26 4.96 4.33 4.42 4.62 5.71
Inventory Turnover		 1.90 1.40 2.02 2.14 2.01 2.11 2.34 2.45 2.52
Fixed Asset Turnover		 0.76 0.86 0.91 0.91 0.90 0.89 0.95 0.93 0.93
Accounts Payable Turnover		 5.06 3.55 5.86 4.50 4.98 5.01 7.51 7.21 7.03
Days Sales Outstanding (DSO)		 93.36 107.03 95.84 85.62 73.55 84.38 82.55 78.98 63.89
Days Inventory Outstanding (DIO)		 191.81 260.52 180.87 170.69 181.19 172.73 156.29 148.92 144.78
Days Payable Outstanding (DPO)		 72.19 102.91 62.32 81.17 73.28 72.79 48.59 50.59 51.91
Cash Conversion Cycle (CCC)		 212.97 264.64 214.39 175.15 181.46 184.33 190.25 177.30 156.76
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 126 149 173 167 162 170 166 166 148
Invested Capital Turnover		 1.65 0.62 0.68 0.90 0.89 0.82 0.77 0.77 0.82
Increase / (Decrease) in Invested Capital		 126 -65 -11 49 36 21 -7.40 -3.00 -14
Enterprise Value (EV)		 394 375 400 327 351 381 372 414 316
Market Capitalization		 254 228 245 172 185 226 208 249 139
Book Value per Share		 ($0.45) $0.05 $0.58 $0.37 ($0.13) $0.50 $0.06 $0.04 ($0.76)
Tangible Book Value per Share		 ($1.04) ($0.55) ($0.01) ($0.22) ($0.71) ($0.09) ($0.43) ($0.45) ($1.13)
Total Capital		 134 152 176 175 167 180 171 174 169
Total Debt		 108 110 117 121 128 120 124 127 148
Total Long-Term Debt		 107 109 116 121 127 119 124 127 148
Net Debt		 99 107 114 113 122 110 119 119 127
Capital Expenditures (CapEx)		 5.05 4.26 6.37 2.64 3.39 2.47 5.46 2.10 1.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 40 34 37 34 29 38 48 47 36
Debt-free Net Working Capital (DFNWC)		 48 37 40 43 34 47 53 55 57
Net Working Capital (NWC)		 47 36 39 42 34 47 53 55 57
Net Nonoperating Expense (NNE)		 4.72 -16 -17 8.59 8.12 5.20 8.45 4.88 12
Net Nonoperating Obligations (NNO)		 99 106 114 113 122 110 119 119 127
Total Depreciation and Amortization (D&A)		 2.17 1.77 2.01 2.25 1.99 2.04 2.08 1.91 2.31
Debt-free, Cash-free Net Working Capital to Revenue		 37.99% 30.27% 30.49% 26.88% 22.51% 28.95% 36.59% 36.65% 28.54%
Debt-free Net Working Capital to Revenue		 46.29% 33.14% 33.01% 33.47% 26.81% 36.18% 40.75% 43.07% 44.87%
Net Working Capital to Revenue		 45.55% 32.45% 32.38% 32.87% 26.21% 35.59% 40.75% 43.07% 44.87%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.35) $0.47 $0.51 ($0.23) ($0.53) ($0.25) ($0.47) ($0.02) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding		 30.40M 30.46M 30.49M 30.47M 30.86M 34.36M 37.02M 34.82M 37.48M
Adjusted Diluted Earnings per Share		 ($0.35) $0.39 $0.42 ($0.14) ($0.53) ($0.25) ($0.47) ($0.02) ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding		 30.40M 36.42M 36.61M 36.66M 30.86M 34.36M 37.02M 34.82M 37.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 30.90M 30.90M 37.03M 37.03M 37.41M 37.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.03 -1.04 -0.12 2.02 -8.11 -1.37 -1.61 3.73 -3.27
Normalized NOPAT Margin		 -24.59% -3.44% -0.34% 5.33% -32.82% -4.21% -4.57% 10.23% -14.10%
Pre Tax Income Margin		 -51.06% 47.02% 42.02% -18.85% -65.80% -20.05% -42.04% -3.06% -64.40%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -2.18 4.48 0.00 -0.23 -2.03 -0.19 0.00 0.00 -1.05
NOPAT to Interest Expense		 -1.53 -0.37 0.00 0.26 -1.51 -0.25 0.00 0.00 -0.45
EBIT Less CapEx to Interest Expense		 -3.46 3.43 0.00 -0.69 -2.66 -0.65 0.00 0.00 -1.20
NOPAT Less CapEx to Interest Expense		 -2.81 -1.41 0.00 -0.20 -2.14 -0.70 0.00 0.00 -0.60
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Lifecore Biomedical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lifecore Biomedical's financial year ends in May. Their financial year 2025 ended on May 25, 2025.

Lifecore Biomedical's net income appears to be on an upward trend, with a most recent value of -$38.72 million in 2025, falling from $13.73 million in 2015. The previous period was $12.01 million in 2024. Check out Lifecore Biomedical's forecast to explore projected trends and price targets.

Lifecore Biomedical's total operating income in 2025 was -$17.25 million, based on the following breakdown:
  • Total Gross Profit: $40.30 million
  • Total Operating Expenses: $57.54 million

Over the last 10 years, Lifecore Biomedical's total revenue changed from $539.26 million in 2015 to $128.87 million in 2025, a change of -76.1%.

Lifecore Biomedical's total liabilities were at $198.12 million at the end of 2025, a 1.0% decrease from 2024, and a 56.8% increase since 2015.

In the past 10 years, Lifecore Biomedical's cash and equivalents has ranged from $360 thousand in 2020 to $19.09 million in 2023, and is currently $17.47 million as of their latest financial filing in 2025.

Over the last 10 years, Lifecore Biomedical's book value per share changed from 8.11 in 2015 to 0.04 in 2025, a change of -99.6%.


Related Companies

Financial statements for NASDAQ:LFCR last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Free Today: Your First Trade Playbook
"Your First Trade Playbook" - normally $29.97 - is free to download today. It walks you through every step, fr...
Profits Run | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
The window is closing
We printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...
American Alternative | Sponsoredtc pixel
A Uranium Major Just Became One of Our Largest Shareholders
IsoEnergy is acquiring the Dieter Lake uranium project in Quebec - but it's not taking cash. Instead, IsoEnerg...
The Tomorrow Investor | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel
NNVC Surges into the Spotlight
NanoViricides (NNVC) has secured FDA Orphan Drug Designation and Rare Pediatric Disease status for its lead an...
Smallcaps Daily | Sponsoredtc pixel